Next Article in Journal
Structural and Immunological Activity Characterization of a Polysaccharide Isolated from Meretrix meretrix Linnaeus
Next Article in Special Issue
Pseudopterosin A: Protection of Synaptic Function and Potential as a Neuromodulatory Agent
Previous Article in Journal
The Structure-Activity Relationship between Marine Algae Polysaccharides and Anti-Complement Activity
Previous Article in Special Issue
Fish Synucleins: An Update
Article Menu

Export Article

Open AccessFeature PaperReview
Mar. Drugs 2016, 14(1), 5;

New Drugs from Marine Organisms in Alzheimer’s Disease

Clinical and Molecular Epidemiology Division, IRCCS “San RaffaelePisana” Via di Valcannuta, 247, RomeI-00166, Italy
Scientific Direction, IRCCS “San RaffaelePisana” Via di Valcannuta, 247, Rome I-00166, Italy
Author to whom correspondence should be addressed.
Academic Editor: George Perry
Received: 5 November 2015 / Revised: 9 December 2015 / Accepted: 21 December 2015 / Published: 25 December 2015
(This article belongs to the Special Issue Marine Compounds and Their Application in Neurological Disorders)
Full-Text   |   PDF [903 KB, uploaded 25 December 2015]   |  


Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neurodegeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions although taking into account successful examples of such approach represented by Cytarabine, Trabectedin, Eribulin and Ziconotide. We review a complexity of the translational research for such a development of new therapies for AD. Bryostatin is a prominent candidate for the therapy of AD and other types of dementia in humans. View Full-Text
Keywords: marine drugs; Alzheimer’s disease; mechanisms of activity; clinical/preclinical studies; bryostatin; new drugs marine drugs; Alzheimer’s disease; mechanisms of activity; clinical/preclinical studies; bryostatin; new drugs

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Russo, P.; Kisialiou, A.; Lamonaca, P.; Moroni, R.; Prinzi, G.; Fini, M. New Drugs from Marine Organisms in Alzheimer’s Disease. Mar. Drugs 2016, 14, 5.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top